Abstract
We describe a patient that developed Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorders (PTLD), which presented as interstitial pneumonia. He had received allogeneic bone marrow transplantation for the treatment of acute myeloid leukemia 17 months before, when he developed hypoxemia requiring emergent admission. Chest computed tomography revealed pulmonary interstitial shadows, but neither hepatomegaly nor lymphadenopathy were detected. Bronchoscopy with lung biopsy revealed a lymphomatous proliferation of EBV-infected B cells. The interstitial pneumonia rapidly deteriorated, but improved dramatically after treatment with anti-CD20 monoclonal antibody (rituximab). This is the first report of a patient with lung EBV-PTLD that presented as interstitial pneumonia and was successfully treated with rituximab.References
- Winer-Muram HT, Gurney JW, Bozeman PM, Krance RA. Pulmonary complications after bone marrow transplantation. Radiol Clin North Am. 1996; 34:97-117. PubMedGoogle Scholar
- Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant. 2003; 31:145-55. PubMedhttps://doi.org/10.1038/sj.bmt.1703806Google Scholar
- van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood. 2001; 98:972-8. PubMedhttps://doi.org/10.1182/blood.V98.4.972Google Scholar
- Clavio M, Gatto S, Beltrami G, Cerri R, Carrara P, Pierri I. First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia. Leuk Lymphoma. 2001; 40:305-13. PubMedGoogle Scholar
- Halkos ME, Miller JI, Mann KP, Miller DL, Gal AA. Thoracic presentations of posttransplant lymphoproliferative disorders. Chest. 2004; 126:2013-20. PubMedhttps://doi.org/10.1378/chest.126.6.2013Google Scholar
- Dodd GD, Ledesma-Medina J, Baron RL, Fuhrman CR. Posttransplant lymphoproliferative disorder: intrathoracic manifestations. Radiology. 1992; 184:65-9. PubMedGoogle Scholar
- Siegel MJ, Lee EY, Sweet SC, Hildebolt C. CT of posttrans-plantation lymphoproliferative disorder in pediatric recipients of lung allograft. Am J Roentgenol. 2003; 181:1125-31. PubMedGoogle Scholar
- Maturen KE, Blane CE, Strouse PJ, Fitzgerald JT. Pulmonary involvement in pediatric lymphoma. Pediatr Radiol. 2004; 34:120-4. PubMedhttps://doi.org/10.1007/s00247-003-1080-9Google Scholar
- Entz-Werle N, Cojean N, Barats A, Eyer D, Munzer M, Uring-Lambert B. Pediatr Transplant. 2003; 7:277-81. PubMedhttps://doi.org/10.1034/j.1399-3046.2003.00091.xGoogle Scholar
- Cohen J, Gandhi M, Naik P, Cubitt D, Rao K, Thaker U. Br J Haematol. 2005; 129:229-39. PubMedhttps://doi.org/10.1111/j.1365-2141.2005.05439.xGoogle Scholar
- Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation. 1999; 68:1517-25. PubMedhttps://doi.org/10.1097/00007890-199911270-00015Google Scholar
- Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994; 330:1185-91. PubMedhttps://doi.org/10.1056/NEJM199404283301703Google Scholar
- Benkerrou M, Jais JP, Leblond V, Durandy A, Sutton L, Bordigoni P. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood. 1998; 92:3137-47. PubMedGoogle Scholar
- van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002; 99:4364-9. PubMedhttps://doi.org/10.1182/blood.V99.12.4364Google Scholar
- Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004; 103:3979-81. PubMedhttps://doi.org/10.1182/blood-2003-12-4287Google Scholar
- Choquet S, Leblond V, Herbrecht R, Socie G, Stoppa AM, Vandenberghe P. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood. 2006; 107:3053-7. PubMedhttps://doi.org/10.1182/blood-2005-01-0377Google Scholar
- van Esser JW, Niesters HG, Thijsen SF, Meijer E, Osterhaus AD, Wolthers KC. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br J Haematol. 2001; 113:814-21. PubMedhttps://doi.org/10.1046/j.1365-2141.2001.02789.xGoogle Scholar